EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision Cancer Medicine 2.0—Oncology in the postgenomic era

Riccardo Masina, Carlos Caldas iD

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13707 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2024. Verfasst von Riccardo Masina und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, UK. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Genomics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CRUK, European Research Council, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic medicine has transformed the lives of patients with cancer by enabling individualised and evidence‐based clinical decision‐making. Despite this progress, the implementation of precision cancer medicine is limited by its dependence on isolated biomarkers. The development of bulk and single‐cell multiomic technologies has revealed the enormous complexity of the cancer ecosystem. Beyond the cancer cell, the tumour microenvironment, macroenvironment and host factors, including the microbiome, profoundly influence the cancer phenotype, and accounting for these enhances the resolution of precision medicine. The advent of robust multiomic profiling and interpretable machine learning algorithms mark the dawn of a new postgenomic era of personalised cancer medicine. In Precision Cancer Medicine 2.0, high‐resolution personalised clinical decision‐making is informed by the comprehensive multiomic profiling of tumour and host, integrated using artificial intelligence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineNeoplasmsGenomicsHumansMedical OncologyMachine LearningTumor Microenvironment

Stichwörter der Autor:innen

cancerdata integrationmachine learningprecision cancer medicinetranslational researchtumour biomarkers

Autor:innen und Institutionen

  • Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, UK.
  • School of Clinical Medicine, University of Cambridge, UK.

ORCID-Profile: Carlos Caldas

Förderung

  • CRUK
  • European Research Council
  • Cancer Research UK

Zitieren

APA

Masina, R., & Caldas, C. (2024). Precision Cancer Medicine 2.0—Oncology in the postgenomic era. Molecular Oncology. https://doi.org/10.1002/1878-0261.13707

Vancouver

Masina R, Caldas C. Precision Cancer Medicine 2.0—Oncology in the postgenomic era. Molecular Oncology. 2024. doi:10.1002/1878-0261.13707

BibTeX
@article{Masina2024,
  author = {Masina, Riccardo and Caldas, Carlos},
  title = {Precision Cancer Medicine 2.0—Oncology in the postgenomic era},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13707}
}
Kostenlos starten →